Cancer BiologyBlood AdvancesPeer-reviewed
YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma
Changying Jiang, Yu Xue, Hong Kim…·Michael L. Wang
This paper identifies YX0798 as a potent, selective, and orally effective CDK9 inhibitor that overcomes therapeutic resistance in lymphoma by inducing transcription reprogramming and cell death.
6 citations